Latest Regulatory Waiver News

Toro Energy sets June 15 Federal Court hearing to seek approval for IsoEnergy's proposed takeover following a shareholder vote.

Synlait Milk is on track to refinance its senior bank facilities by June 30, 2026, replacing a $130 million shareholder loan from Bright Dairy with a new two-year loan. The company reported a preliminary net loss of $12 million for the first four months of 2026, reflecting operational headwinds and the recent North Island asset sale.

Santana Minerals has raised A$130 million through a two-tranche placement and plans a share purchase plan to accelerate development of its Bendigo Ophir Gold Project. The equity raise aims to fund early works, exploration, and equipment procurement ahead of final resource consents.

Lotus Resources has completed a A$76 million placement to bolster its financial position as it accelerates uranium production at the Kayelekera Mine, aiming for steady state output and first shipments in Q2 2026.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.

Blue Energy Limited invites eligible shareholders to participate in a discounted Share Purchase Plan, offering shares at $0.005 each, matching a recent institutional placement price. The plan aims to raise up to $250,000, providing retail investors a rare chance to buy shares at a significant discount.

Blue Energy Limited has successfully raised $3.2 million through a two-tranche placement, complemented by a proposed $250,000 share purchase plan, to fund drilling and pipeline development in Queensland’s North Bowen Basin.

Pacific Edge has successfully raised NZ$16 million through an upsized equity placement, surpassing its initial target and setting the stage for a planned NZ$5 million Share Purchase Plan. The funds aim to accelerate clinical and commercial milestones, including regaining Medicare coverage for its cancer diagnostic tests.

TruScreen Limited has obtained a waiver from NZ RegCo allowing it to allot oversubscribed shares up to 10 business days after its capital raising offer closes, subject to shareholder approval. This move aims to streamline the company’s NZ$3 million placement and share purchase plan.